Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Sep;34(9):1655–1659. doi: 10.1128/aac.34.9.1655

Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates.

E G Arathoon 1, J R Hamilton 1, C E Hench 1, D A Stevens 1
PMCID: PMC171900  PMID: 2285277

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is an important nosocomial infection problem. Colonization appears to be more common than invasive disease is. Eradication of colonization or the carrier state could limit the spread of MRSA, thus reducing the potential for mortality and morbidity in other patients. The detection of patients with MRSA infection in a rehabilitation ward led to a study of the combination of novobiocin-rifampin in vivo and in vitro. We found that 300 mg of rifampin plus 500 mg of novobiocin orally twice daily for 5 days, in 18 courses of treatment given to 12 patients, resulted in the clearing of MRSA in 79% of the evaluable courses and 81% of the evaluable sites. A second course cleared MRSA from one of the patients with a treatment failure. Side effects were not noted. All 18 pretherapy isolates were susceptible to either drug in vitro, but 1 of 2 posttherapy isolates was rifampin resistant. Timed-kill studies demonstrated that the rate of killing was the same with either drug alone or both drugs together. Pretherapy isolates from treatment successes or failure were killed at the same rate by the drug combination. However, with the rifampin-resistant isolate killing ceased after 48 h. Results of this study suggest that previously untreated patients are likely to have isolates that are susceptible to the combination of drugs and that the combination is commonly effective in eradicating MRSA carriage. Since the regimen is orally administered, and thus convenient, in conjunction with other measures it has the promise of reducing the spread of MRSA in hospitals.

Full text

PDF
1655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S428–S432. doi: 10.1093/clinids/5.supplement_3.s428. [DOI] [PubMed] [Google Scholar]
  2. Bartzokas C. A., Paton J. H., Gibson M. F., Graham F., McLoughlin G. A., Croton R. S. Control and eradication of methicillin-resistant Staphylococcus aureus on a surgical unit. N Engl J Med. 1984 Nov 29;311(22):1422–1425. doi: 10.1056/NEJM198411293112207. [DOI] [PubMed] [Google Scholar]
  3. Dixson S., Brumfitt W., Hamilton-Miller J. M. In vitro activity of combinations of antibiotics against Staphylococcus aureus resistant to gentamicin and methicillin. Infection. 1985 Jan-Feb;13(1):35–38. doi: 10.1007/BF01643619. [DOI] [PubMed] [Google Scholar]
  4. Drusano G. L., Townsend R. J., Walsh T. J., Forrest A., Antal E. J., Standiford H. C. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother. 1986 Jul;30(1):42–45. doi: 10.1128/aac.30.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Haley R. W., Hightower A. W., Khabbaz R. F., Thornsberry C., Martone W. J., Allen J. R., Hughes J. M. The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit. Ann Intern Med. 1982 Sep;97(3):297–308. doi: 10.7326/0003-4819-97-3-297. [DOI] [PubMed] [Google Scholar]
  6. Johnston B. L., Kwok R. Y., Mulligan M. E. In vitro activity of novobiocin and rifampin alone and in combination against oxacillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 1987 Nov;8(3):137–147. doi: 10.1016/0732-8893(87)90164-7. [DOI] [PubMed] [Google Scholar]
  7. KIRBY W. M., HUDSON D. G., NOYES W. D. Clinical and laboratory studies of novobiocin, a new antibiotic. AMA Arch Intern Med. 1956 Jul;98(1):1–7. doi: 10.1001/archinte.1956.00250250007001. [DOI] [PubMed] [Google Scholar]
  8. Klimek J. J., Marsik F. J., Bartlett R. C., Weir B., Shea P., Quintiliani R. Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital. Am J Med. 1976 Sep;61(3):340–345. doi: 10.1016/0002-9343(76)90370-3. [DOI] [PubMed] [Google Scholar]
  9. LUBASH G., VAN DER MEULEN J., BERNTSEN C., Jr, TOMPSETT R. Novobiocin: a laboratory investigation. Antibiotic Med Clin Ther (New York) 1956 Apr;2(4):233–240. [PubMed] [Google Scholar]
  10. NICHOLS R. L., FINLAND M. Novobiocin; a limited bacteriologic and clinical study of its use in forty-five patients. Antibiotic Med Clin Ther (New York) 1956 Apr;2(4):241–257. [PubMed] [Google Scholar]
  11. Pearman J. W., Christiansen K. J., Annear D. I., Goodwin C. S., Metcalf C., Donovan F. P., Macey K. L., Bassette L. D., Powell I. M., Green J. M. Control of methicillin-resistant Staphylococcus aureus (MRSA) in an Australian metropolitan teaching hospital complex. Med J Aust. 1985 Jan 21;142(2):103–108. [PubMed] [Google Scholar]
  12. Sabath L. D., Barrett F. F., Wilcox C., Gerstein D. A., Finland M. Methicillin resistance of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (Bethesda) 1968;8:302–306. [PubMed] [Google Scholar]
  13. Spicer W. J. Three strategies in the control of staphylococci including methicillin-resistant Staphylococcus aureus. J Hosp Infect. 1984 Dec;5 (Suppl A):45–49. doi: 10.1016/0195-6701(84)90029-x. [DOI] [PubMed] [Google Scholar]
  14. WRIGHT W. W., PUTNAM L. E., WELCH H. Novobiocin; serum concentrations and urinary excretion following oral administration in man. Antibiotic Med Clin Ther (New York) 1956 May;2(5):311–316. [PubMed] [Google Scholar]
  15. Walsh T. J., Auger F., Tatem B. A., Hansen S. L., Standiford H. C. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin. J Antimicrob Chemother. 1986 Jan;17(1):75–82. doi: 10.1093/jac/17.1.75. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES